Nakagawa S
Artif Organs. 1980 May;4(2):94-102. doi: 10.1111/j.1525-1594.1980.tb03912.x.
In order to ascertain if the potential benefits claimed for hemofiltration (HF) are supportable, chronic thrice-weekly HF therapy has been assessed in a group of nine uremic patients who had previously been stabilized on conventional hemodialysis (HD) for a mean of 17.8 months at a frequency of 3 x 5 hours/week. Changes between the termination of HD (= initiation of HF) and the last three months were observed in multifactorial parameters. No significant differences were observed in any parameter except the frequency of hypotensive episodes and the pretreatment levels of conventional waste metabolites. The latter were higher on HF than HD and the frequency of hypotension, 2% in HF, was less than the 8% frequency observed in HD, despite much larger body weight reductions per HF treatment. Also, the effects of HF on hypertension and hyperlipidemia were not significantly better than observed on HD therapy. Our preliminary conclusions are that HF is superior to HD in both the ease and safety of fluid removal and there is virtual elimination of the disequilibrium syndrome. However, HF offers no other obvious advantages over conventional hemodialysis therapy.
为了确定血液滤过（HF）所宣称的潜在益处是否成立，我们对一组9名尿毒症患者进行了评估，这些患者此前已在常规血液透析（HD）治疗下稳定了平均17.8个月，透析频率为每周3次，每次5小时。观察了从HD治疗终止（即HF治疗开始）到最后三个月期间多因素参数的变化。除了低血压发作频率和常规废物代谢产物的预处理水平外，在任何参数上均未观察到显著差异。后者在HF治疗时高于HD治疗，并且低血压发作频率在HF治疗时为2%，低于HD治疗时观察到的8%，尽管每次HF治疗时体重减轻幅度更大。此外，HF对高血压和高脂血症的治疗效果并不比HD治疗显著更好。我们的初步结论是，HF在液体清除的简便性和安全性方面优于HD，并且几乎消除了失衡综合征。然而，与传统血液透析治疗相比，HF没有其他明显优势。
